Cholangiocarcinoma Pipeline Insight: Therapeutic analysis of 70+ pipeline therapies and 70+ pharmaceutical companies
Cholangiocarcinoma Pipeline is majorly witnessing TAS-120, AG-120, E7090, and E7090 as the most anticipating therapies.
DelveInsight’s ‘Cholangiocarcinoma (CCA) Pipeline Insights’ report provides a comprehensive portfolio of pipeline therapies and key pharmaceutical companies actively engaged in the domain.
The report lays down complete information on the drug profiles, stages of their clinical development, MoA, RoA, molecule type, and drug delivery platform. Besides, the report proffers a view on
Some of the crucial takeaways from the Cholangiocarcinoma Pipeline report:
- The Cholangiocarcinoma pipeline comprises TT-00420 (TransThera Biosciences), and STP-705 (Sirnaomics) in Phase I clinical stage of development, while CX-4945 (Senhwa Biosciences) and MIV-818 (Medivir) are in Phase I/II stage.
- In mid-stage of development of Cholangiocarcinoma pipeline therapies comprises HMPL-453 (Hutchison Medipharma) and E7090 (Eisai) are in Phase II with Bintrafusp alfa (EMD Serono) in Phase II/III stage of clinical trials.
- AG-120 (Agios Pharmaceuticals) and TAS-120 (Taiho Oncology) are in the late-stage of Cholangiocarcinoma pipeline.
- Key companies dedicated to advance the Cholangiocarcinoma drug pipeline are: Medivir, Hutchison Medipharma, Agios Pharmaceuticals, TransThera Biosciences, Senhwa Biosciences, Eisai, EMD Serono, Taiho Oncology, Sirnaomics, RedHill Biopharma, MacroGenics, Chia Tai Tianqing Pharmaceutical Group, Sirtex Medical, Delcath Systems Inc. Innovent Biologics, PCI Biotech AS, Basilea Pharmaceutica, QED Therapeutics, Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Toray Industries, Bold Therapeutics and several others.
- On March 1, 2021, Agios Pharmaceuticals submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Ivosidenib tablets (AG-120) as a potential treatment for patients with previously treated isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma.
- In May 2020, Bold Therapeutics entered into an option agreement with an Hana Pharm Co Ltd for exclusive rights to BOLD 100 in South Korea. Under the terms of the agreement, Bold Therapeutics and Hana Pharm will collaborate for a planned phase Ib/IIa adaptive trial in gastric, pancreatic, colorectal and bile duct (cholangiocarinoma) cancer.
Cholangiocarcinomais cancer that arises from the cells lining the bile duct, a drainage system for the bile that is produced by the liver. This condition, also known as bile duct cancer, is an uncommon form of cancer that occurs mostly in people older than age 50, though it can occur at any age. Cholangiocarcinomas are part of the family of tumors known as adenocarcinomas, which originate in glandular tissue. Less commonly, they’re squamous cell carcinomas, which develop in the squamous cells that line the digestive tract.
Source: Globenews Wire
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.